We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+12.98%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$95.4B
AUM Growth
+$9.26B
(+11%)
Cap. Flow
-$707M
Cap. Flow
% of AUM
-0.74%
Top 10 Holdings %
Top 10 Hldgs %
25.21%
Holding
4,380
New
32
Increased
1,513
Reduced
2,146
Closed
67
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Russell 1000 ETF
IWB
|
+$99.9M |
| 2 |
Uber
UBER
|
+$71M |
| 3 |
Broadcom
AVGO
|
+$36.2M |
| 4 |
iShares Russell 2000 ETF
IWM
|
+$32.6M |
| 5 |
lululemon athletica
LULU
|
+$32.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ATVI
Activision Blizzard
ATVI
|
+$139M |
| 2 |
Apple
AAPL
|
+$72.7M |
| 3 |
VMW
VMware, Inc
VMW
|
+$47.1M |
| 4 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$42.3M |
| 5 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$35.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.73% |
| 2 | Financials | 13% |
| 3 | Healthcare | 12.09% |
| 4 | Consumer Discretionary | 11.32% |
| 5 | Industrials | 9.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3076
PDS Biotechnology
PDSB
$43.4M
| $168K | ﹤0.01% |
33,795
+1,281
| +4% | +$6.37K |
|
3077
Vodafone
VOD
$37.4B
| $168K | ﹤0.01% |
19,277
-140
| -0.7% | -$1.28K |
|
3078
Foghorn Therapeutics
FHTX
$360M
| $167K | ﹤0.01% |
25,961
-465
| -2% | -$2.01K |
|
3079
Kodiak Sciences
KOD
$2.84B
| $167K | ﹤0.01% |
55,069
+314
| +0.6% | +$698 |
|
3080
DHI Group
DHX
$173M
| $165K | ﹤0.01% |
63,807
+403
| +0.6% | +$1.04K |
|
|
CUTR
3081
DELISTED
Cutera, Inc.
CUTR
| $165K | ﹤0.01% |
46,863
+16,687
| +55% | +$50.8K |
|
3082
BRC Inc
BRCC
$250M
| $165K | ﹤0.01% |
45,450
+235
| +0.5% | +$809 |
|
3083
Canadian Natural Resources
CNQ
$93.8B
| $164K | ﹤0.01% |
5,016
+32
| +0.6% | +$1.04K |
|
3084
Seer Inc
SEER
$120M
| $164K | ﹤0.01% |
84,573
+522
| +0.6% | +$928 |
|
3085
Verrica Pharmaceuticals
VRCA
$87.3M
| $164K | ﹤0.01% |
2,239
-104
| -4% | -$4.27K |
|
3086
Mistras Group
MG
$512M
| $163K | ﹤0.01% |
22,336
-18,423
| -45% | -$113K |
|
3087
Ternium
TX
$10.6B
| $163K | ﹤0.01% |
3,840
-2,683
| -41% | -$104K |
|
3088
Expensify
EXFY
$245M
| $163K | ﹤0.01% |
65,915
-52
| -0.1% | -$135 |
|
3089
Ascendis Pharma A/S
ASND
$16.8B
| $162K | ﹤0.01% |
1,290
+22
| +2% | +$2.19K |
|
3090
Humacyte
HUMA
$194M
| $162K | ﹤0.01% |
56,875
+1,930
| +4% | +$4.95K |
|
|
AKYA
3091
DELISTED
Akoya BioSciences
AKYA
| $161K | ﹤0.01% |
33,059
+9,012
| +37% | +$37.4K |
|
3092
Actinium Pharmaceuticals
ATNM
$25M
| $161K | ﹤0.01% |
31,648
+882
| +3% | +$4.54K |
|
|
IGMS
3093
DELISTED
IGM Biosciences
IGMS
| $160K | ﹤0.01% |
19,204
+508
| +3% | +$2.95K |
|
3094
J. Jill
JILL
$283M
| $159K | ﹤0.01% |
6,186
+664
| +12% | +$18.8K |
|
|
JOYY
3095
JOYY Inc
JOYY
$3.75B
| $159K | ﹤0.01% |
3,999
+265
| +7% | +$10.5K |
|
3096
Ispire Technology
ISPR
$98.2M
| $158K | ﹤0.01% |
12,989
+9,763
| +303% | +$100K |
|
3097
ENI
E
$77.5B
| $157K | ﹤0.01% |
4,619
-200
| -4% | -$6.5K |
|
|
PWOD
3098
DELISTED
Penns Woods Bancorp
PWOD
| $157K | ﹤0.01% |
6,972
-166
| -2% | -$3.52K |
|
|
ASRT
3099
DELISTED
Assertio
ASRT
| $157K | ﹤0.01% |
9,760
+1,666
| +21% | +$41.2K |
|
3100
Weibo
WB
$1.95B
| $156K | ﹤0.01% |
14,291
-1,360
| -9% | -$15.4K |
|
Similar funds
VAM
RhumbLine Advisers's Q4 2023 Portfolio in Review
As of Q4 2023, RhumbLine Advisers held 4,380 positions worth $95.4B, up 11% from $86.2B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Trading was light in Q4 2023: portfolio turnover was 2.3%. RhumbLine Advisers opened 32 new positions and exited 67, leaving the 4,380-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 28% of assets, up from 27% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q4 2023 buy was CRH: 83,048 shares worth $5.74M.
- RhumbLine Advisers added most to iShares Russell 1000 ETF in Q4 2023, an estimated $99.9M increase.
- RhumbLine Advisers's biggest Q4 2023 reduction was Apple, cutting an estimated $72.7M.
- RhumbLine Advisers fully exited Activision Blizzard in Q4 2023, selling an estimated $139M.
- RhumbLine Advisers's ten largest holdings make up 25% of its $95.4B portfolio in Q4 2023.
- RhumbLine Advisers opened 32 new positions and closed 67 in Q4 2023.
- RhumbLine Advisers's portfolio value rose 11% quarter-over-quarter to $95.4B.
Based on RhumbLine Advisers's 13F filing for Q4 2023, filed 8 Feb 2024.